CAMP Study Section Reviewers

Chairperson Phillip Furmanski, Ph.D. Professor and Chairman Department of Biology Professor of Pathology  School of Medicine New York University Members    Adunyah Samuel, Ph.D. Associate Professor Chairman Department of Biochemistry Meharry Medical College Boxer Linda, M.D., Ph.D. Associate Professor Department of Medicine Stanford University Campana Dario, M.D., Ph.D. Professor Department of Hematology/Oncology  St. Judes' Children's Hospital Christopher Denny, M.D. Professor Department of Pediatrics UCLA Medical Center Flynn Daniel, PhD Associate Director for Basic Research, MBR Cancer Center Associate Professor, Microbiology/Immunology/Cell Biology West Virginia University Frisch Steven, Ph.D. Associate Professor The Burnham Institute La Jolla Cancer Research Center Gallick Gary, Ph.D. Professor Department of Cancer Biology The University of Texas, M.D. Anderson Cancer Center Goodfellow Paul, Ph.D. Professor  Department of Surgery and Genetics Washington University- School of Medicine Hanks Steven, Ph.D. Professor Department of Cell Biology Vanderbilt University Hedrick-Ellenson Lora, MD Associate Professor Director, Division of Gynecologic Pathology Department of Pathology Weill Medical College of Cornell University Hess Jay L., M.D., Ph.D. Director of Hematopathology Department of Pathology and Laboratory Medicine University of Pennsylvania Kulez-Martin Molly, Ph.D. Professor Director of Research Department of Dermatology Oregon Health & Science University

Ladisch Stephan, M.D. Professor Department of Pediatrics/Biochemistry Children's Research Institute Children's National Medical Center Le Beau Michelle, Ph.D. Professor Department of Medicine Division of Biological Sciences University of Chicago Licht Jonathan, M.D. Associate Professor The Cancer Center Mount Sinai School of Medicine Louis David, M.D. Associate Professor Molecular Neuro-Oncology Laboratory Massachusetts General Hospital Nucifora Giuseppina, Ph.D. Associate Professor of Pathology University of Illinois Cancer Center  Nuñez Gabriel, MD Associate Professor Department of Pathology University of Michigan Med School Pietenpol Jennifer, Ph.D. Associate Professor Department of Biochemistry Vanderbilt University School of Medicine Rabson Arnold B., M.D. Professor Department of Molecular Genetics and Microbiology  University of Medicine and  Dentistry of NJ Rempel Sandra, Ph.D. Director Molecular Neuro-Oncology Laboratory Hermelin Brain Tumor Center Henry Ford Hospital Tan Tse-Hua, Ph.D. Professor Department of Immunology Baylor College of Medicine Wellstein Anton, M.D.,Ph.D. Professor Lombardi Cancer Center Georgetown University

Cance Molecular Pathobiology STUDY SECTION (CAMP) [CAMP Roster]

The Cance Molecular Pathobiology (CAMP) Study Section reviews laboratory and clinical investigations of cancer, including studies of cell growth and differentiation as they relate to cancer. These include molecular biology and cytogenetics of tumor markers, as well as factors that may influence initiation of oncogenic transformation such as: cytokines, lymphokines, growth factors, and hormones. Applications dealing with the molecular and pathogenic mechanisms involved in the development of brain and lymphoid malignancies are also reviewed in this study section. Specific areas covered by CAMP: Transition from normal to neoplastic state: modulation at the cellular and molecular levels by growth factors and cytokines, oncogenes, and signal transduction pathways. Neoplastic pathology of lymphoid malignancies: cancer biology, tumor diagnosis, tumor transplantation, cytogenetics, and the immunopathology of these malignancies, where the emphasis is on the tumor rather than the immunological aspects. Pathogenesis of brain tumors: tumor markers, oncogenes, cytogenetics, growth factors, and receptors. Cell cycling and apoptosis: disruption in signaling pathways and the prevention of normal differentiation that lead to onset of malignancy. Shared Coverage/Interests: With PTHB regarding changes in normal and tumor cells. When studies deal primarily with cellular and molecular divergence between normal and malignant cells, CAMP should be considered. With MEP in modulation of gene expression and signaling pathways during carcinogenesis by cytokines, and growth factors. When studies focus on the primary stages of neoplastic transformation, (e.g., initiation) CAMP should be considered. With CPA in studies that pertain to loss of tumor suppression leading to the onset of oncogenic transformation or carcinogenesis. When the primary emphasis is on the phenotypic/genotypic changes occurring in the cell rather than the mechanism of damage induction, CAMP should be considered. CAMP has the following shared interests outside the ONC IRG: With CDF-1 in cell growth and differentiation. When the study relates to modulation by cytokines and growth factors resulting in cancer, CAMP should be considered. With CDF-5 in cell cycle and apoptosis. When the focus is on signaling pathways differences between normal and transformed cells, CAMP should be considered. With BCE in hormonal regulation of abnormal growth. When the goal of the study is to compare hormone regulation between normal and malignant tissues, CAMP should be considered. With BDCN-4 in etiology, detection, and mechanism of brain tumors. When the study relates to fundamental cellular and molecular neoplastic mechanisms, CAMP should be considered. With HEM-1 & 2 in pathological hematopoietic progenitor/stem cells and myelocyte function. When the focus is signal transduction, growth factor regulation, or oncogene expression leading to neoplasia, CAMP should be considered.